Understanding the Grp94 Chaperone for Disease Treatment
Elucidating the Mechanistic Details of the Grp94 Molecular Chaperone through an Integrated Computational and Experimental Approach
['FUNDING_OTHER'] · MIAMI UNIVERSITY OXFORD · NIH-11123271
This project aims to understand how a protein called Grp94 works inside our cells, which could help develop new treatments for diseases like diabetes, cancer, and heart conditions.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MIAMI UNIVERSITY OXFORD (nih funded) |
| Locations | 1 site (OXFORD, UNITED STATES) |
| Trial ID | NIH-11123271 on ClinicalTrials.gov |
What this research studies
Our cells rely on special proteins called chaperones, like Grp94, to correctly fold other proteins, which is essential for cell health. When Grp94 doesn't work right, it can lead to serious health problems such as type 2 diabetes, various cancers, and heart or brain diseases. This research uses both computer models and lab experiments to uncover the exact steps Grp94 takes to do its job. By learning these fundamental details, we hope to find better ways to design medicines that specifically target Grp94 to correct protein folding issues. This approach could lead to more effective treatments with fewer side effects than current options.
Who could benefit from this research
Good fit: This foundational research does not directly involve patient participation, but future clinical trials stemming from this work would likely target individuals with diseases linked to protein misfolding, such as type 2 diabetes, cancer, or neurodegenerative conditions.
Not a fit: Patients seeking immediate treatment options would not directly benefit from this basic science project, as its goal is to understand fundamental mechanisms rather than to test new therapies.
Why it matters
Potential benefit: If successful, this research could provide foundational knowledge for developing new, more targeted drugs to treat diseases caused by misfolded proteins, such as type 2 diabetes, cancer, and neurodegenerative disorders.
How similar studies have performed: While the Hsp90 superfamily of chaperones is well-studied, the specific mechanistic details of Grp94 are less understood, making this a novel approach to a promising drug target.
Where this research is happening
OXFORD, UNITED STATES
- MIAMI UNIVERSITY OXFORD — OXFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KRAVATS, ANDREA N — MIAMI UNIVERSITY OXFORD
- Study coordinator: KRAVATS, ANDREA N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus, Cancers, Cardiovascular Diseases, Degenerative Neurologic Disorders, Disease